Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
Author(s) -
Michael H. Woodworth,
Emma Neish,
Nancy S. Miller,
Tanvi Dhere,
Eileen M. Burd,
Cynthia Carpentieri,
Kaitlin L. Sitchenko,
Colleen S. Kraft
Publication year - 2017
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.02327-16
Subject(s) - fecal bacteriotherapy , clostridium difficile , feces , asymptomatic , transplantation , medicine , immunology , microbiology and biotechnology , biology , antibiotics
Fecal microbiota transplantation is an efficacious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thought to depend on appropriate fecal donor screening. FDA guidance for regulation of this procedure is in flux, but screening and manufacture of fecal material from asymptomatic donors present many challenges to clinical laboratories. This minireview summarizes FDA regulatory changes, principles of donor selection, and recommended laboratory screening practices for fecal microbiota transplantation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom